Drug
Gevokizumab clinical trials
Also written XOMA 052.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
21 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 5 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 5
XOMA (US) LLC (16) · Institut de Recherches Internationales Servier (2) · University of Zurich (1) · NSABP Foundation Inc (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)
Studies
Open first, then newest update. How each study uses gevokizumab is read from its arms, and is right about nine times in ten.
Testing it · 21
- A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant ChemotherapyWithdrawnPhase 2NSABP Foundation IncNCT05178576Written as Gevokizumab
- Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)TerminatedPhase 3Institut de Recherches Internationales ServierNCT02375685Written as Gevokizumab
- Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)TerminatedPhase 3Institut de Recherches Internationales ServierNCT01965145Written as Gevokizumab
- A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's DiseaseWithdrawnPhase 1/2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT01211977Written as XOMA 052
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedPhase 3XOMA (US) LLCNCT02326740Written as gevokizumab
- An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma GangrenosumTerminatedPhase 3XOMA (US) LLCNCT02315417Written as gevokizumab
- A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma GangrenosumTerminatedPhase 3XOMA (US) LLCNCT02318914Written as gevokizumab
- The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear DiseaseCompletedPhase 2XOMA (US) LLCNCT01950312Written as gevokizumab
- Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma GangrenosumCompletedPhase 2XOMA (US) LLCNCT01882504Written as gevokizumab
- Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid ArthritisSuspendedPhase 2XOMA (US) LLCNCT00777816Written as XOMA 052
- Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisTerminatedPhase 3XOMA (US) LLCNCT02258867Written as Gevokizumab
- Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the HandCompletedNot applicableXOMA (US) LLCNCT02293564Written as gevokizumab
- Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne VulgarisCompletedPhase 2XOMA (US) LLCNCT01498874Written as gevokizumab
- Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedPhase 2XOMA (US) LLCNCT01882491Written as gevokizumab
- Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the HandCompletedPhase 2XOMA (US) LLCNCT01683396Written as gevokizumab
- Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 DiabetesCompletedPhase 2XOMA (US) LLCNCT00998699Written as Xoma 052
- Effects of XOMA 052 on Insulin Production in Type 1 DiabetesCompletedPhase 2University of ZurichNCT01788033Written as XOMA 052
- Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedPhase 2XOMA (US) LLCNCT01144975Written as XOMA 052
- Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes MellitusCompletedPhase 1/2XOMA (US) LLCNCT00513214Written as XOMA 052
- Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin MonotherapyCompletedPhase 2XOMA (US) LLCNCT01066715Written as XOMA 052
See all 21 studies that test gevokizumab →
Given in every arm · 1 — gevokizumab is usual care beside what is tested
Codes
What other systems call gevokizumab · ClinicalTrials.gg INT005584
- MeSH (NLM) C547697gevokizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QX3JU54GYQGEVOKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5554924GevokizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97945GevokizumabOne source FDA
- DrugBank DB12119One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C547697 | gevokizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QX3JU54GYQ | GEVOKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5554924 | Gevokizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97945 | Gevokizumab | One source FDA |
| DrugBank | DB12119 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.